Sanofi faces a make-or-break year, saying it’s ready to put a 3-prong R&D strategy to a pivotal test
With the help of some key development partners, Sanofi set out today to try and prove to an increasingly skeptical group of investors that it can control its own destiny with a late-stage pipeline bristling with blockbuster contenders.
But with a decade-long track record largely absent of big, in-house success stories and its “blockbuster” Dengvaxia in a shambles, caught up in a global safety crisis that has crushed its potential, that’s no easy task.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
